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Here we studied the role of IGF-I on the regulation
of the sodium/iodide symporter (NIS) gene expres-
sion in FRTL-5 thyroid cells. IGF-I did not modify
NIS mRNA levels but inhibited TSH- and forskolin-
induced NIS mRNA expression in a dose-depen-
dent manner. We explored the signaling pathways
by which IGF-I mediates the repression of NIS ex-
pression. Inhibition of either the MAPK kinase or
PKC activities had no effect. Interestingly, inhibi-
tion of PI3K blocked IGF-I repression of TSH-
induced NIS mRNA and protein levels. This effect
takes place at the transcriptional level, as IGF-I
inhibited TSH-induced transcription of a luciferase
reporter construct containing a 2.8-kb DNA frag-
ment of the rat NIS promoter. The inhibitory effect
of IGF-I on the NIS promoter was blocked by the
PI3K inhibitor LY294002 and was mimicked by
overexpression of a vector harboring the constitu-
tively activated catalytic subunit of PI3K. Using in-
ternal deletions of the NIS promoter, we defined a
region from 1,947 to 1,152 responsible for the
observed IGF-I/PI3K inhibitory effect. When fused
to a heterologous promoter, this region inhibits
transcription in response to IGF-I. These results
demonstrate a central role for PI3K in the repres-
sion of NIS gene transcription by IGF-I and suggest
the existence, within the above defined promoter
region, of putative PI3K-responsive elements.
(Molecular Endocrinology 16: 342–352, 2002)
IODIDE UPTAKE IS the first step in thyroid hormonebiosynthesis (1), the primary function of the thyroid
gland. Iodide transport occurs across the basolateral
membrane of thyroid follicular cells in an active trans-
port process mediated by the sodium iodide sym-
porter (NIS) (2). Iodide is subsequently incorporated by
thyroid peroxidase (TPO) into the thyroglobulin (Tg)
molecule. All of these steps are stimulated by TSH, the
primary hormone regulating the functions of differen-
tiated thyroid cells. Although TSH regulation of iodide
transport has been widely reported (3–5), the cloning
of the rat NIS cDNA by Dai et al. (2) allowed the study
of the molecular mechanisms involved in TSH regula-
tion of NIS gene expression. TSH, via cAMP, induces
the activity of the NIS protein (6, 7) and increases NIS
mRNA levels (8). TSH stimulation of NIS mRNA ex-
pression in FRTL-5 cells is inhibited by RA (9), TNF,
ceramide, TGF1, and aging (10). The cloning of the
rat NIS promoter (11, 12) allowed initiation of the study
of NIS transcriptional regulation. A TSH-responsive
element was identified between positions 420 and
385 (13) and a thyroid transcription factor-1 (TTF-1)
binding site was identified between 245 and 230
(14). In the distal promoter, Ohno et al. (12) identified a
short enhancer, called NUE (NIS upstream enhancer),
another important regulatory element for TSH-regu-
lated transcriptional activation. This element contains
binding sites for the thyroid-specific transcription
factors TTF-1 and Pax-8, and a cAMP responsive
element-like sequence. NUE confers thyroid-specific
transcriptional activity to the NIS gene and responds
to TSH/cAMP. The cAMP response therefore requires
the binding of Pax-8 and the integrity of the cAMP-
responsive element sequence.
Insulin and IGF-I are additional important factors for
thyroid function that collaborate with TSH in the reg-
ulation of thyroid proliferation and differentiation. The
biological effects of insulin and IGF-I are mediated by
activation of their cell surface receptors, which pos-
sess tyrosine kinase activity (15). After ligand binding,
insulin and IGF-I receptor activities converge on the
phosphorylation of insulin receptor substrates (IRS-1
and IRS-2), which then act as docking proteins for
SH2-containing proteins such as PI3K. The interaction
of the PI3K-regulatory subunit p85 with tyrosine-phos-
phorylated IRS-1 leads to activation of the p110 cat-
alytic subunit. This results in activation of several pro-
tein kinases, including Akt and certain PKC isoforms.
Grb-2 is another IRS-1-associated protein; their inter-
action leads to activation of the small GTP-binding
protein Ras, which then initiates the Raf-1/MAPK ki-
nase (MEK)/MAPKs ERK1 and ERK2 cascade. Stimu-
lation of any of these pathways can lead to activation/
inhibition of target genes by transcriptional or
posttranscriptional mechanisms (16). Although the in-
sulin/IGF-I signaling pathways involved in the regula-
tion of thyroid-specific genes remain unknown, several
reports have shown their importance in regulating thy-
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roid gene transcription. Insulin and IGF-I stimulate Tg
and TPO mRNA expression (17, 18). Both hormones
increase Tg transcription, and their effects are additive
to those of TSH/cAMP (17). Our group has identified
response elements for insulin and IGF-I within the Tg
(19) and TPO (20) promoters and reported that the
hormonal regulation of both genes is mediated mainly
by the forkhead thyroid transcription factor-2 (TTF-2),
a thyroid-specific transcription factor that binds to the
promoter of both genes (21, 22). In addition, TTF-2
gene expression is stimulated by cAMP and insulin/
IGF-I (23). Insulin and IGF-I also stimulate transcription
of the TSH receptor gene (24).
Here we studied the role of IGF-I in the regulation
of NIS gene expression and the signaling pathways
involved in IGF-I action. The results show that IGF-I
inhibits TSH/forskolin-induced NIS mRNA levels.
This effect is PI3K mediated, as its specific inhibitor,
LY294002, prevents IGF-I inhibition of TSH induc-
tion; this effect was also observed when NIS protein
levels were determined. Using transient transfection
assays, we show that IGF-I inhibits TSH-stimulated
transcriptional activity of a 2.8-kb NIS promoter, but
no inhibition was observed using constructs with
internal deletions from 1,947 to 1,152. When
fused to a heterologous promoter, this region inhib-
its transcription in response to IGF-I, indicating that
it contains IGF-I-responsive elements. Presence of
the PI3K inhibitor LY294002 prevents IGF-I inhibi-
tion, and cotransfection with a constitutively active
form of the PI3K catalytic subunit reduces TSH-
dependent transcriptional activation. Our results
show that via PI3K activation, IGF-I interferes with
TSH induction of NIS gene expression; we define a
region within the promoter responsible for the IGF-I
inhibitory effect.
RESULTS
Insulin and IGF-I Do Not Increase NIS
mRNA Levels
Insulin and IGF-I are important hormones for thyroid
function; both stimulate expression of the thyroid-
specific genes Tg and TPO (17, 18), as well as the
transcription factor TTF-2 (23), and potentiate the
stimulatory action of TSH on the expression of these
genes. We performed Northern hybridization assays to
examine the role of insulin and IGF-I in NIS gene
expression. Starved FRTL-5 cells were insulin or IGF-I
treated, and NIS mRNA levels were compared with
those observed in untreated cells or cells treated
with TSH or forskolin. TSH and forskolin stimulate NIS
expression, as has been extensively described (8), but
neither IGF-I nor insulin has any effect on NIS mRNA
levels compared with untreated cells (Fig. 1).
IGF-I Inhibits TSH- or Forskolin-Induced NIS
mRNA Levels
Although neither insulin nor IGF-I increased NIS mRNA
content in FRTL-5 cells, we analyzed whether these
hormones could regulate TSH and forskolin effects.
Starved FRTL-5 cells were treated with TSH (1 nM) or
forskolin (10 M), alone or in the presence of increasing
concentrations of IGF-I. The results show that IGF-I
inhibited the stimulatory effect of TSH or forskolin in a
dose-dependent manner (Fig. 2, A and B, respective-
ly). Maximum inhibition of NIS mRNA levels was
reached at 100 ng/ml of IGF-I. Like IGF-I, insulin in-
hibited NIS mRNA expression induced by TSH or for-
skolin in a dose-dependent fashion; maximum inhibi-
tion was observed at 10 M insulin (not shown). These
data suggested that insulin and IGF-I may interfere
with cAMP induction of NIS mRNA expression.
Neither MEK nor PKC Is Involved in IGF-I-
Dependent Inhibition of TSH-Stimulated NIS
mRNA Expression
To further analyze the mechanism by which IGF-I in-
hibits TSH-induced NIS mRNA expression, we studied
the signaling pathways involved in IGF-I action. After
binding of IGF-I to its cell surface receptors, a signal-
ing cascade is initiated, leading to the activation of
several kinases including MEK and PKC. To assess
the involvement of these kinases in the IGF-I effect, we
treated starved FRTL-5 cells with the specific inhibi-
tors of these kinases, PD98059, which inhibits MEK
activity, and bisindolyl maleimide I (BIS), which inhibits
PKC activity, and determined NIS mRNA levels in re-
sponse to TSH or TSH plus IGF-I. Figure 3A shows the
results obtained with these inhibitors as well as with
H89, a specific inhibitor of PKA. TSH induction of NIS
mRNA expression is only partially inhibited in the pres-
ence of H89. This confirms previous observations by
Ohno et al. (12) suggesting that TSH induction of NIS
gene expression occurs in both a PKA-dependent and
-independent manner. TSH retained the ability to in-
Fig. 1. IGF-I and Insulin Do Not Increase NIS mRNA Levels
Starved FRTL-5 cells were treated with TSH, forskolin
(Forsk), IGF-I, or insulin (Ins) for 24 h and then harvested for
RNA extraction. A representative Northern blot hybridized
with the rat NIS probe is shown. Methylene blue staining of
the 18S rRNA shows equal sample loading.
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crease NIS mRNA levels in the presence of PD98059
or BIS. None of these inhibitors (PD98059 or BIS)
abolished IGF-I inhibition of TSH induction, indicating
that neither MEK nor PKC is involved in IGF-I action.
The inhibitors have no effect when added alone and do
not substantially affect mRNA levels in cells treated
with IGF-I in the absence of TSH (not shown). The lack
of any effect in response to PD98059 or BIS was not
due to a loss of inhibitor function, demonstrated by
immunoblot assays (Fig. 3B). Starved FRTL-5 cells
treated with IGF-I show increased levels of phospho-
ERK1/ERK2, downstream targets of MEK (25), com-
pared with untreated cells; the presence of PD98059
abolished this stimulation (Fig. 3B, upper panel). BIS
activity was examined by determining the activation of
the PKC target, protein kinase D (PKD), using a spe-
cific antibody that recognizes phosphorylated PKD
(26). The phorbol ester phorbol-12,13-dibutyrate
(PDBu) stimulates PKD phosphorylation, but no phos-
pho-PKD is detected in the presence of BIS (Fig. 3B,
lower panel). These results clearly indicate that both
inhibitors were active at the concentrations used.
Inhibition of PI3K Prevents Suppression of TSH-
Induced NIS mRNA and Protein Expression
by IGF-I
PI3K is one of the central enzymes implicated in insulin
and IGF-I signaling. To determine whether PI3K is
required for IGF-I inhibition of TSH induction of NIS
gene expression, starved FRTL-5 cells were pre-
treated with the PI3K inhibitor LY294002 before the
addition of TSH, forskolin, and IGF-I. LY294002 pre-
treatment increased NIS mRNA levels in TSH-treated
cells and slightly enhanced the messenger level in
cells treated with IGF-I (Fig. 4A). Interestingly, IGF-I
inhibition of TSH induction is not observed in the pres-
ence of LY294002. Similar results were obtained using
wortmannin (25–100 nM), another PI3K inhibitor (not
shown). When forskolin was used instead of TSH, the
results resembled those found for TSH, except that
LY294002 did not increase NIS mRNA levels in fors-
kolin-treated cells. These data suggest that PI3K in-
terferes with NIS gene expression induced by the
cAMP signaling pathway. We next determined
whether the changes in NIS mRNA levels in response
to TSH, IGF-I, and LY294002 correlated with changes
in NIS protein levels. Western blot analyses were per-
formed using a specific anti-NIS antibody that reacts
with two main NIS species, the mature 80- to 90-kDa
form and a partially processed 60- to 65-kDa NIS form
(6). Due to the long half-life of the NIS protein, FRTL-5
cells were maintained for 7 d in starvation medium,
before hormone addition, to completely deplete cells
of NIS protein (7). Cells maintained for 7 d in starvation
medium have no detectable NIS protein, and TSH
treatment of cells led to an increase in NIS protein
levels (Fig. 4C), as previously reported (6, 7). IGF-I
completely inhibits NIS protein expression in response
to TSH, and the presence of LY294002 prevents this
effect. All together, the results suggest that PI3K in-
terferes with TSH-dependent NIS mRNA and protein
induction and may mediate the IGF-I inhibitory effect
observed.
IGF-I Inhibits TSH-Dependent Transcriptional
Activation of the NIS Gene
To study whether IGF-I regulates transcription of the
rat NIS gene, we cloned a 2.8-kb fragment of the rat
NIS promoter, as described in Materials and Methods.
This region contains the NUE, a regulatory element
necessary for a full TSH response (12). Luciferase
reporter DNA constructs containing the full-length
DNA fragment or 5-deletion derivatives were tran-
siently transfected into FRTL-5 cells and assayed for
transcriptional activity in response to TSH and/or IGF-I
(Fig. 5A). As previously described (12), the 2,854-bp
Fig. 2. IGF-I Inhibits TSH- or Forskolin-Stimulated NIS mRNA Expression
Starved FRTL-5 cells were treated with TSH (panel A) or forskolin (Forsk; panel B) alone or in the presence of increasing IGF-I
concentrations (1, 10, or 100 ng/ml) for 24 h and then harvested for RNA analysis. A representative Northern blot hybridized with
rat NIS probe is shown. Methylene blue staining of the 18S rRNA shows equal sample loading.
344 Mol Endocrinol, February 2002, 16(2):342–352 Garcı´a et al. • PI3K and NIS Expression
 by on May 20, 2010 mend.endojournals.orgDownloaded from 
DNA fragment (pNIS-2.8) showed significant stimula-
tion of transcription by TSH, whereas the 5-deletion
constructs, pNIS-2, pNIS-1.2, and pNIS-0.5, which
lacked the enhancer, showed no stimulation of tran-
scription or only trace levels, as was the case for
pNIS-0.5. IGF-I had no effect on the transcriptional
activity of any construct when added alone, although
IGF-I inhibited the TSH-induced transcriptional activa-
tion of the construct containing the full promoter,
pNIS-2.8; this indicates that IGF-I signaling interferes
with TSH induction of NIS transcription. To analyze the
mechanism of NIS repression by IGF-I, we inserted a
region containing the NUE element upstream of the
promoter region in pNIS-1.2 (pNIS-NUE-1.2) and
pNIS-0.5 (pNIS-NUE-0.5). Transient transfection anal-
yses with these two constructs and pNIS-2.8 showed
that all three constructs expressed significant lucif-
erase activity in response to TSH, but only pNIS-2.8
exhibited a reduction in luciferase activity when IGF-I
was added together with TSH (Fig. 5B). These results
indicate that IGF-I does not interfere with NUE activa-
tion by TSH and requires the region from 1,947 to
1,152 for the inhibition of the TSH-dependent stim-
ulation of NIS transcription.
To confirm that this region is IGF-I responsive, the
NIS-regulatory region from 1,947 to 1,152 was
inserted upstream from the -globin TATA box of the
luciferase expression vector TATA-LUC (20). This con-
struct (pNIS-0.8-TL) and the control vector TATA-LUC
were transiently transfected into FRTL-5 cells and as-
sayed for transcriptional activity in response to TSH
and/or IGF-I. The results indicate that pNIS-0.8-TL
shows almost 50% inhibition by IGF-I, both alone or in
the presence of TSH, whereas no effect is observed on
the TATA-LUC control vector, which lacked the regu-
latory region (Fig. 5C). These results clearly indicate
that the 1,947 to 1,152 region of the rat NIS gene
contains IGF-I-responsive regulatory elements.
PI3K Mediates the Inhibition of TSH-Induced NIS
Promoter Activity by IGF-I
To investigate whether PI3K was required for the ob-
served IGF-I inhibitory action on NIS promoter activity,
we studied the effect of LY294002 on TSH-induced
transcriptional activation of pNIS-2.8, alone or in the
presence of IGF-I. The results (Fig. 6A) resemble those
obtained in Northern blot assays, i.e. the PI3K inhibitor
LY294002 completely blocked IGF-I repression of the
transcriptional activation by TSH. These data indicate
that PI3K activity is necessary for suppression of TSH-
induced NIS gene expression by IGF-I. To ask whether
PI3K activation inhibited TSH induction of NIS gene
transcription, we next transfected FRTL-5 cells with
the pNIS-2.8, pNIS-NUE-1.2, or pNIS-NUE-0.5 con-
structs, with or without an expression vector for the
constitutively active PI3K catalytic subunit, p110-
CAAX. Overexpression of p110-CAAX caused a strik-
ing reduction in the stimulation of pNIS-2.8 transcrip-
tion by TSH, thus mimicking the effect of IGF-I (Fig.
6B). Conversely, the transcriptional activation of pNIS-
NUE-1.2 and pNIS-NUE-0.5 by TSH is not affected by
p110-CAAX overexpression. These results indicate
that p110-CAAX does not block NUE activation by
Fig. 3. The Inhibitors H89, PD98059, and BIS Do Not Block
IGF-I Inhibition of TSH-Induced NIS mRNA Expression
A, Starved FRTL-5 cells were pretreated with the inhibitors
H89, PD98059 (PD), or BIS, 30 min before addition of TSH
and IGF-I. After 24 h, cells were harvested for RNA analysis.
A representative Northern blot hybridized with rat NIS probe
and methylene blue staining of the 18S rRNA are shown. B,
Starved FRTL-5 cells were pretreated with inhibitors PD or
BIS, 30 min before addition of IGF-I (100 ng/ml) or PDBu (100
nM) for 15 min. Western blot analyses performed with 20 g
of total protein and probed with antiphospho-ERK1/ERK2
(upper panel) and antiphospho-PKD (lower panel) are shown.
Immunodetection of -actin shows equal sample loading.
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TSH, and that the region between1,947 and1,152
responds to PI3K activation, leading to inhibition of
transcriptional activation by TSH.
DISCUSSION
The data presented here demonstrate that IGF-I inhib-
its TSH stimulation of NIS gene expression. These
results are in accordance with previous reports show-
ing that IGF-I inhibited iodide uptake stimulated by
TSH in FRTL-5 cells (27, 28); this effect was also seen
when the cAMP analog 8-Br-cAMP was used instead
of TSH (28). We also demonstrate that IGF-I interferes
with cAMP signaling, because IGF-I prevents the in-
duction of NIS mRNA expression by forskolin. These
results, in addition to the reports mentioned above (27,
28), thus demonstrate cross-talk between IGF-I sig-
naling and the cAMP transduction pathway; this
cross-talk may take place downstream of cAMP gen-
eration, because IGF-I did not affect the TSH-induced
cAMP levels, as reported by Saji and Kohn (28).
We studied the signaling pathways involved in the
IGF-I inhibitory effect on the induction of NIS gene
expression by TSH. Using specific inhibitors of the
distinct kinases involved in the most important signal-
ing pathways operating in thyroid cells, we found that
the presence of H89, a PKA inhibitor, decreased but
did not abolish TSH induction of NIS mRNA levels. It is
likely that cAMP regulation of NIS gene expression is
mediated by PKA-dependent and -independent path-
ways, as suggested by Ohno et al. (12). A new cAMP
cascade has been identified that involves the guanine
nucleotide exchange factor (GEF), called Epac (29) or
cAMP-GEF (30). Epac, which is regulated directly by
cAMP, is a GEF for the small GTPase Rap-1 and is
expressed in many tissues, including thyroid (30). In
dog thyroid cells, Rap-1 activation has been described
in response to TSH/cAMP (31) and, in the WRT rat
thyroid cell line, TSH activates Rap1 through a cAMP-
mediated, PKA-independent mechanism (32). It re-
mains to be determined whether this cAMP-Epac-
Rap-1 pathway is involved in TSH-dependent
stimulation of NIS gene expression.
Contrary to observations with H89, the presence of
the PI3K inhibitor LY294002 results in superinduction
of NIS mRNA levels by TSH, suggesting a role for PI3K
in TSH-dependent signaling transduction pathways.
These data concur with recent results involving PI3K in
the stimulation of thyroid cell proliferation in response
Fig. 4. The PI3K Inhibitor LY294002 Blocks IGF-I Inhibition of TSH- and Forskolin-Induced NIS mRNA and TSH-Induced
Protein Expression
A and B, Starved FRTL-5 cells were pretreated with LY294002 (LY) 30 min before addition of TSH, forskolin (Forsk), or IGF-I,
and cells were collected 24 h later. Representative Northern blots hybridized with rat NIS probe are shown. Methylene blue
staining of the 18S rRNA shows equal sample loading. C, Western blot analysis of NIS expression. FRTL-5 cells were starved for
7 d and then pretreated with LY294002 (LY) 30 min before TSH and IGF-I addition. After 24 h, cells were collected for membrane
protein preparation. Membrane protein (5 g) was resolved in 12% SDS-PAGE, transferred to nitrocellulose filters, and probed
with anti-NIS antibody. For loading control, Ponceau S staining of a blot fragment is shown.
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Fig. 5. IGF-I Inhibits TSH-Induced NIS Gene Transcription
A and B, FRTL-5 cells were transfected with 2 g of RSV-CAT and 2 pmol of the reporter construct containing the complete
NIS promoter, pNIS-2.8, or the 5-deletion derivatives pNIS-2, pNIS-1.2, or pNIS-0.5 (panel A), or the internal deletion constructs
pNIS-NUE-1.2 or pNIS-NUE-0.5 (panel B). C, FRTL-5 cells were transfected with 2 g of RSV-CAT and 2 pmol of pNIS-0.8-TL
or the control vector TATA-LUC. After transfection, cells were maintained 72 h in starvation medium and then treated with TSH
and IGF-I. After 24 h, cells were harvested and luciferase and CAT activity were determined. Relative luciferase activity is the value
of light units, normalizing the results to CAT activity derived from RSV-CAT. The NIS promoter activity is expressed as the x-fold
induction over the basal levels (1 in A and B; 100 in C) of starved cells (basal). The data represent the mean  SE of at least
four independent experiments.
Garcı´a et al. • PI3K and NIS Expression Mol Endocrinol, February 2002, 16(2):342–352 347
 by on May 20, 2010 mend.endojournals.orgDownloaded from 
to TSH via cAMP (33, 34). PI3K signaling is thus re-
quired for a mitogenic response to TSH but, in view of
our results, it inhibits the stimulation of NIS gene ex-
pression by TSH. Interestingly, we did not observe this
superinduction when forskolin was used instead of
TSH (Fig. 4). One explanation for this result may derive
from the fact that forskolin stimulates cAMP produc-
tion by direct activation of the adenylyl cyclase, thus
eliminating possible PI3K activation by G protein -
subunits, a PI3K activation mechanism (35). Although
it was not the aim of this study to analyze the signaling
pathways involved in TSH-dependent activation of NIS
gene expression, it would be of great interest to in-
vestigate the existence of this possible mechanism of
PI3K activation in response to TSH.
IGF-I inhibition of TSH-stimulated NIS mRNA and
protein expression was blocked by the PI3K inhibitor
LY294002. We observed similar results with wortman-
nin at nanomolar doses (not shown). The absence of
effect in response to PD98059 and BIS should not be
attributed to a lack of function, as we observed an
inhibitory effect by both compounds in Western blots
for phospho-ERK1/ERK2 and phospho-PKD, respec-
tively. The results clearly indicate that PI3K interferes
with TSH-induced NIS gene expression and suggest
that PI3K may be involved in IGF-I action. Previous
data from Cass and Meinkoth (36) suggested a role for
PI3K in the regulation of NIS expression. They re-
ported that transfection of WRT thyroid cells with the
Ras mutant RasV12C40, which signals preferentially
through PI3K, resulted in a reduction of NIS protein
levels, whereas Tg protein levels were not affected. It
appears that NIS and Tg gene expression are regu-
lated in a different manner. The authors proposed that
RasV12C40-dependent signals might also down-
regulate the expression and/or activity of Pax-8, a
transcription factor involved in the regulation of NIS
expression (12), or affect NIS activity through a post-
transcriptional mechanism. Before the cloning of the
NIS cDNA (2), Saji and Kohn (28) proposed a posttran-
scriptional mechanism by which insulin/IGF-I regu-
lated TSH induction of the iodide porter system. Al-
though these results are not in doubt, an additional
regulatory mechanism at the transcriptional level can-
not be ruled out. Taking advantage of the cloning and
characterization of the rat NIS promoter (11, 12), we
cloned a 2.8-kb DNA fragment of the rat NIS promoter
to study the role of IGF-I in regulating NIS gene tran-
scription. Our results from transient transfection as-
says, with reporter constructs containing the full-
length DNA fragment or 5 deletions, confirm the
requirement of the NUE for a potent TSH response, as
reported previously (12). We also showed that tran-
scriptional activation by TSH was inhibited by IGF-I,
although the extent of inhibition was lower than that
observed in Northern blot studies. This difference may
be explained by the suggested posttranscriptional
regulation (28) and/or the presence of regulatory ele-
ments upstream of the DNA fragment studied.
The results obtained with the PI3K inhibitor
LY294002 indicated that PI3K activity was required for
inhibition of TSH-induced transcriptional activation by
Fig. 6. PI3K Involvement in NIS Promoter Repression by IGF-I
A, FRTL-5 cells were transfected with 2 pmol of the reporter construct pNIS-2.8 and 2 g of RSV-CAT. After 72 h in starvation
medium, cells were treated with LY294002 (LY) 30 min before addition of TSH and IGF-I. B, FRTL-5 cells were transfected with
2 pmol of the reporter constructs pNIS-2.8, pNIS-NUE-1.2, or pNIS-NUE-0.5, and 2 g of RSV-CAT, with 2 g of either
pSG5-p110-CAAX (p110) or the empty vector. After transfection, cells were maintained 72 h in starvation medium and then
treated with TSH. At 24 h after hormone treatment, cells were harvested, and luciferase and CAT activity were determined.
Relative luciferase activity was determined as in Fig. 5. NIS promoter activity is expressed as the x-fold induction over basal levels
(1) of starved cells. The data represent the mean  SE of at least three independent experiments.
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IGF-I. This observation was confirmed by the results of
transient transfection assays with the constitutively
active form of the PI3K catalytic p110 subunit, p110-
CAAX, showing inhibition of transcriptional activation
by TSH. Although there are multiple PI3K isoforms
(37), these findings suggest that signaling pathways
leading to activation of the PI3K p110 subunit could
result in the inhibition of NIS gene expression. It none-
theless remains to be elucidated which PI3K subtype,
sensitive to LY294002 and wortmannin inhibition, me-
diates IGF-I effects. To confirm the results observed
with PI3K inhibitor, we performed transfection assays
with the dominant negative form of the PI3K-regula-
tory subunit, p85iSH2-N. The results did not pro-
vide significant information, as transfection with this
mutant resulted in the loss of the majority of the cells
(not shown), i.e. drastic inhibition of PI3K activity leads
to cell death. This concurs with recent reports on PI3K
in cell cycle progression in thyroid cells (33, 34), in
addition to its role in cell survival signaling (38). Added
to our findings, these results clearly demonstrate the
importance of PI3K in thyroid cell function. Although
we have no physiological explanation for the IGF-I-
inhibitory effect observed on NIS gene expression, the
results with LY294002 and the dominant positive mu-
tant of PI3K suggest that situations leading to activa-
tion of the PI3K pathway may affect NIS expression
levels. In this respect, activation of Akt, one of the
downstream targets of PI3K, has been shown in sev-
eral thyroid tumors (39). Moreover, the expression
level of PTEN, a 3-phosphatase that converts phos-
phatidylinositol (3,4)P2 to PtIns(4)P, and PtIns (3,4,5)P3
to PtIns (4,5)P2, thus inactivating Akt, is decreased in
neoplasic thyroid cells and in thyroid tumors (40).
These findings and our results may explain the down-
regulation of NIS expression found in many thyroid
cancers (1). The elucidation of the mechanism by
which PI3K downregulates NIS expression will aid in
understanding the absence of iodide symporter activ-
ity in thyroid tumors.
To delimit the region within the NIS promoter re-
sponsible for the IGF-I effect, several deletions of the
NIS promoter were studied. The results indicate that
IGF-I does not interfere with the TSH activation of
NUE. The region from 1,947 to 1,152 seems to be
necessary for IGF-I/PI3K inhibition of TSH induction of
the NIS promoter; it contains IGF-I-responsive ele-
ments, as it could inhibit transcription of a heterolo-
gous promoter in response to IGF-I. Computer analy-
sis of this region revealed the existence of several
TG/ATTT elements; this sequence is the core motif of
insulin and IGF-I response elements found in the pro-
moter of several genes that are negatively regulated by
insulin/IGF-I (16). It has recently been reported that a
subfamily of forkhead transcription factors, the FKHR
proteins, can bind this motif and are targets of PI3K
(41). This evidence suggests that these proteins, or
related family members, may confer the inhibitory
effect observed on NIS transcription. Additional ob-
servations by our group, indicating that the thyroid
transcription factor TTF-2 mediates transcriptional ac-
tivation of thyroid-specific genes by insulin/IGF-I (23),
suggest a general role for forkhead proteins in medi-
ating insulin/IGF-I effects on transcription. Further
studies will elucidate the role of FKHR proteins on NIS
gene expression and will give new insight into the
mechanisms by which forkhead transcription factors
regulate the transcription of cAMP-stimulated genes.
MATERIALS AND METHODS
Materials
Tissue culture medium, bovine TSH, and bovine insulin were
purchased from Sigma (St. Louis, MO). IGF-I was obtained
from Peprotech (Rocky Hill, NJ). Forskolin, LY294002,
PD98059, H89, bisindolyl maleimide I HCl, and wortmannin
were purchased from Calbiochem (La Jolla, CA). Donor calf
serum and DMEM were obtained from Life Technologies, Inc.
(Gaithersburg, MD), and Nytran and nitrocellulose filters were
obtained from Schleicher & Schuell, Inc. (Keene, NH). The
luciferase assay kit was purchased from Promega Corp.
(Madison, WI). [-32P]dCTP and [-32P]ATP were obtained
from ICN Biochemicals, Inc. Restriction enzymes were ob-
tained from Roche Molecular Biochemicals (Indianapolis, IN);
the Luminol kit and streptavidin-horseradish peroxidase con-
jugate, antiphospho-ERK1/ERK2, and anti--actin antibodies
were obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Anti-NIS antibody was a generous gift from Dr. N.
Carrasco (Albert Einstein College of Medicine, Bronx, NY).
Anti-phospho-PKD antibody was kindly donated by Dr. T.
Iglesias (Instituto de Investigaciones Biome´dicas, Madrid,
Spain).
Cell Culture
FRTL-5 cells (ATCC CRL 8305, American Type Culture Collec-
tion, Manassas, VA) were a generous gift of Dr. L. D. Kohn
(Edison Biotechnical Institute, Athens, OH); these cells had the
properties described (42, 43), were diploid, and their doubling
time with TSH was 36 h. Cells were cultured in Coon’s modified
Ham’s F-12 medium supplemented with 5% donor calf serum
and a six-hormone mixture [1 nM TSH, 10 g/ml insulin, 10
ng/ml somatostatin, 5 g/ml transferrin, 10 nM hydrocortisone,
and 10 ng/ml glycyl-L-histidyl-L-lysine acetate; complete me-
dium (42)]. The effect of hormones and growth factors was
studied by starving near-confluent cells for TSH and insulin in
the presence of 0.2% serum (starvation medium) for 72 h. For
NIS protein analyses, cells were starved for 7 d, after which the
ligands were added to culture medium at the following concen-
trations: 1 nM TSH, 10 g/ml insulin, 100 ng/ml IGF-I, 10 M
forskolin, and 100 nM PDBu (unless otherwise indicated). Inhib-
itors were added to the cells 30 min before hormone addition at
the following concentrations: 10 M H89, 50 M PD98059, 25–
100 nM wortmannin, 10 M LY294002, and 1 M bisindolyl
maleimide I.
RNA Extraction and Northern Blot Analysis
Total RNA was isolated by the guanidinium-thiocyanate-
phenol procedure (44) from FRTL-5 cells after different treat-
ments. Total RNA (20 g) was separated in 1% agarose gels
containing 2.2 M formaldehyde. RNA was blotted onto Nytran
filters as suggested by the manufacturer. Methylene blue
staining of the blots revealed the integrity of the RNA and the
presence of equal amounts in each lane. Hybridization and
washing were carried out with the NIS-specific probe (2),
labeled by random oligo priming.
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Protein Extraction and Western Blot Analysis
Membranes from FRTL-5 cells were prepared with protease
inhibitors as described previously (45). Briefly, FRTL-5 cells
were collected and homogenized in a buffer containing 250
mM sucrose, 10 mM HEPES-KOH (pH 7.5), 1 mM EDTA, 2
g/ml leupeptin, and 2 g/ml aprotinin. Cell homogenates
were centrifuged (100,000  g, 60 min, 4 C) to obtain mem-
brane fractions, and the pellet was resuspended in buffer as
above. Whole-cell extracts were obtained by resuspending
the cell pellet in a buffer containing 50 mM HEPES (pH 7.0), 2
mM MgCl2, 250 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1%
NP40, 1 mM dithiothreitol, 2 M Na3VO4, 10 mM NaF, 1 mM
phenylmethylsulfonyl fluoride, 10 g/ml pepstatin A, 10
g/ml aprotinin, and 10 g/ml leupeptin. Protein concentra-
tion was determined according to Bradford (46) with the
Bio-Rad Laboratories, Inc. (Hercules, CA) protein assay kit.
For immunodetection of NIS, membrane fractions were di-
luted 1:2 with loading buffer and heated (37 C, 30 min) before
electrophoresis. Total cell extract proteins (25 g) or mem-
brane proteins (5 g) were separated by 8% or 12% SDS-
PAGE for phospho-PKD or phospho-ERK1/ERK2 and NIS,
respectively, and then transferred to nitrocellulose mem-
brane. Ponceau S staining of the blots for NIS detection
showed equal protein loading. Membranes were blocked (1
h, room temperature) in TBS-T buffer (20 mM Tris-HCl, 137
mM NaCl, 0.1% Tween-20, pH 7.5) containing 5% nonfat
milk. Western analyses for NIS detection were performed
with anti-NIS antibody (1:5,000 dilution) (45). PKD was de-
tected using a noncommercial antibody to phosphorylated
PKD (26). Commercial antibodies were used for ERK1/ERK2
or -actin immunodetection at 1:5,000 or 1:2,000, respec-
tively. After incubation with antibodies in TBS-T containing
5% nonfat milk, membranes were washed four times with
TBS-T buffer and incubated with a streptavidin-horseradish
peroxidase conjugate (1:2,000), followed by four washes of
10 min each with TBS-T buffer. Immunoreactive bands were




DNA fragments from the rat NIS promoter, corresponding to
the regions 2,841 to 13 and 1,941 to 13 (11, 12), were
amplified from FRTL-5 genomic DNA by PCR, using forward
primers with a BamHI (5-GCTATGGATCCCGAAGTG-
GCACTCACAACAT GTACC-3) and SacI sites (5-TCCTGC-
GAGCTCTAAGCCTCTGCTAGG-3), respectively, and re-
verse primer with a BamHI site (5-CGCAGGATCCATG-
GAGACAGGTGACTCG-3). The fragments were cloned into
pGEM-T vector (Promega Corp.), cleaved by BamHI or SacI
and BamHI, and subcloned into pBSLuc2 vector (22).
pNIS-1.2 and pNIS-0.5
DNA fragments were amplified from pNIS-2 by PCR, using
forward primers with a SacI site (5-CAACACGA GC-
TCCAGCCCTCCCTGGTGGC-3; 5-AAGAAGAGCTCCAA-
GAGAACCTGAGTGC-3) and the reverse primer described
above.
pNIS-NUE-1.2 and pNIS-NUE-0.5
A DNA fragment containing the NUE element was cleaved by
SacI and inserted into the SacI site of pNIS-1.2 (pNIS-NUE-
1.2) and pNIS-0.5 (pNIS-NUE-0.5).
pNIS-0.8-TL
The DNA fragment was PCR-amplified from pNIS-2.8, using
the forward primer with a SacI site (5-TCCTGCGAGCTCTA-
AGCCTCTGCTAGG-3) and reverse primer with a BamHI site
(5-ATGCTGGGATCCTCGCGGTCATGCCGGTGC-3). The
fragment was cloned into pGEM-T vector, cleaved by SacI,
and subcloned into the TATA-LUC vector (20). The fidelity of
all constructs was confirmed by sequencing on an automatic
DNA sequencer (Perkin-Elmer Corp., Norwalk, CT).
Transfection
FRTL-5 cells were plated at 1.5  106 cells per 90 mm-
diameter tissue culture dish, 48 h before transfection. Trans-
fections were performed by calcium phosphate coprecipita-
tion as described previously (47). Cells were transfected with
2 pmol of test plasmid and 2 g of Rous sarcoma virus-
chloramphenicol acetyltransferase (RSV-CAT) (48), used to
monitor transfection efficiency. PI3K pathway involvement
was studied using an expression plasmid containing the con-
stitutively active catalytic PI3K subunit, pSG5-p110-CAAX, or
the dominant negative form, p85iSH2-N (49). To study the
effect of pSG5-p110-CAAX on pNIS-2.8, pNIS-NUE-1.2, and
pNIS-NUE-0.5, 2 g of RSV-CAT, 2 pmol of test plasmid, and
2 g of pSG5-p110-CAAX or the empty vector pSG5 (to
adjust total plasmid quantity) were used. To study the effects
of TSH and IGF-I, transfected cells were cultured in starvation
medium (72 h) and then treated with 1 nM TSH and/or 100
ng/ml IGF-I. The PI3K inhibitor LY294002 was studied by
addition at 10 M, 30 min before hormone addition. After
24 h, cells were collected for LUC and CAT activity assay, as
described previously (50, 51).
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